Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb crossover polysomnography study of MK-4305 in primary insomnia
2008-006018-97Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of suvorexant in Insomnia (2 arms), sponsored by Merck & Co. Primary endpoints: Sleep efficiency, Latency to persistent sleep and 1 more. Started Apr 2009; status: terminated.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2008-006018-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006018-97.